Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment

Vir Biotechnology, Inc.

Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.
Underwriters exercised in full the 30-day option to purchase an additional 2,647,058 shares on Feb 26, 2026.
Offering closed on February 27, 2026; net proceeds after discounts and expenses not disclosed.
Goldman Sachs, Leerink Partners, Evercore, and Barclays acted as representatives of the underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.